001 Bruno Godinho, University of Massachusetts Medical School
Neuroactive siRNA Scaffold Enables Broad Distribution and Robust Gene Silencing Throughout the Central Nervous System: Preclinical Studies in Large Mammals

002 Julia Alterman, University of Massachusetts Medical School
Potent and long-term RNA interference-based silencing of huntingtin expression in the CNS

023 Nadia Ayat, Case Western Reserve University
Formulation of targeted long-term, stabile ECO/siRNA nanoparticles with long-term stability for triple negative breast cancer therapy

031 Ian Cardle, University of Washington
Traceless Isolation of CD8+ T Cells by Reversible, Aptamer-Based Selection for CAR T Cell Therapy

045 Ahmed ElDesoky, University of Sadat City
In vitro evaluation of cytotoxic effect of combining two LNA-Gapmer antisense oligonucleotides against Telomerase RNA component (hTR) and mRNA of centromere protein B (CENP-B) in Hepatocellular carcinoma cells.

048 Chantal Ferguson, UMMS
The impact of CAG-repeat expansions on Huntingtin mRNA subcellular localization and accessibility

055 Suzan Hammond, University of Oxford
Peptide Enhanced Delivery of Oligonucleotides to the Skeletal Muscle and CNS

096 Ochaba Joseph, Ionis Pharmaceuticals
A novel role for autophagy in antisense oligonucleotide activity and trafficking

105 Elaine Pirie, Ionis Pharmaceuticals
Mouse Genome-Wide Association Studies and Systems Genetics Uncovers Genes Involved in Antisense Oligomer Uptake, Efficacy, and Inflammation

126 Yu-Lin Su, City of Hope Beckman Research Institute
Targeted delivery of CpG-miR-146a mimic oligonucleotides as a therapeutic strategy to reduce NF-kB-mediated pathogenic inflammation and myeloid leukemia progression

133 Anton Turanov, University of Massachusetts Medical School
Improvement of the chemical modifications of anti-sFLT1 siRNAs for the treatment of preeclampsia.

137 Amita Vaidya, Case Western Reserve University
Nanoparticle-mediated RNAi against DANCR mediates effective TNBC therapy by targeting multiple oncogenic pathways

152 Patricia Müller, Goethe University
Light-Inducible AntimiRs as a Therapeutic Agent

153 Philippine Aupy, University of Versailles Saint Quentin
Preclinical studies of exon 51 tcDNA for DMD therapy: identifying and avoiding sequence specific toxicity

154 Xiulong Shen, UT Southwestern Medical Center
Activating frataxin expression by antisense oligonucleotides and singlestranded siRNAs targeting the GAA repeat expansion